Effectiveness of 2023-2024 Coronavirus Disease 2019 (COVID-19) Vaccines in Pregnant Women

Obstet Gynecol. 2026 Apr 1;147(4):569-573. doi: 10.1097/AOG.0000000000006145. Epub 2025 Dec 11.

Abstract

Pregnant women are at higher risk of severe coronavirus disease 2019 (COVID-19) compared with nonpregnant women of reproductive age. During 2023-2024, the Centers for Disease Control and Prevention recommended COVID-19 vaccination for everyone aged 6 months or older, including pregnant women. Using a test-negative design, we assessed the effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated emergency department (ED) and urgent care setting encounters among pregnant women aged 18-45 years presenting for care with COVID-19 symptoms from September 2023 to August 2024. Vaccine effectiveness against COVID-19-associated ED and urgent care encounters of one 2023-2024 COVID-19 vaccine dose was 58% (95% CI, 24-77%) among pregnant women and 37% (95% CI, 29-44%) among nonpregnant women of the same age. The 2023-2024 COVID-19 vaccines were associated with a decrease in COVID-19-associated ED and urgent care encounters among pregnant women and nonpregnant women of reproductive age.

MeSH terms

  • Adolescent
  • Adult
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Emergency Service, Hospital / statistics & numerical data
  • Female
  • Humans
  • Middle Aged
  • Pregnancy
  • Pregnancy Complications, Infectious* / prevention & control
  • Pregnant People
  • SARS-CoV-2
  • United States / epidemiology
  • Vaccine Efficacy*
  • Young Adult

Substances

  • COVID-19 Vaccines